Royalty Pharma (RPRX) total liabilities

Total liabilities · fiscal 2025
$9.91B

Royalty Pharma (RPRX) had total liabilities of $9.91B at the end of fiscal 2025 (December 31, 2025). That is 25.7% higher than the $7.88B of fiscal 2024. Figures as of 18 Nov 2026, 20:14 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Total liabilities, fiscal 2025
$9.91B
Change on fiscal 2024
+25.7%
Growth, 5 years
+10.1% a year
Highest on record
$9.91Bfiscal 2025
Lowest on record
$6.12Bfiscal 2020
Fiscal years on record
72019–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Royalty Pharma total liabilities, in more detail

Over the five fiscal years to 2025 total liabilities grew at a compound 10.1% a year. Across the 7 fiscal years on record (2019–2025), the highest was $9.91B in fiscal 2025 and the lowest $6.12B in fiscal 2020.

History · 7 fiscal years

Total liabilities by fiscal year

Royalty Pharma total liabilities, year by year

Royalty Pharma (RPRX) total liabilities by fiscal year
Fiscal yearTotal liabilitiesChangeYear ended
2025$9.91B 25.7% up
2024$7.88B 25.1% up
2023$6.30B 13.6% down
2022$7.29B 0.3% up
2021$7.27B 18.7% up
2020$6.12B 2.9% down
2019$6.31B—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest.

How to read it

It is broader than debt: read it against total assets, and remember that for a bank or an insurer customer deposits and policy reserves are liabilities too.

More on RPRX

Royalty Pharma, figure by figure

Royalty Pharma (RPRX) overview: price, valuation and scorecardAll health care companies by market value

Royalty Pharma total liabilities: questions and answers

How large are Royalty Pharma's total liabilities?

Royalty Pharma (RPRX) had total liabilities of $9.91B at the end of fiscal 2025 (December 31, 2025). That is 25.7% higher than the $7.88B of fiscal 2024.

What is the growth rate of Royalty Pharma's total liabilities?

Over the five fiscal years to 2025 total liabilities grew at a compound 10.1% a year.

What are the highest and lowest total liabilities figures on record for Royalty Pharma?

Across the 7 fiscal years on record (2019–2025), the highest was $9.91B in fiscal 2025 and the lowest $6.12B in fiscal 2020.

How is Royalty Pharma's total liabilities calculated?

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest. For Royalty Pharma it is on record here for 7 fiscal years, 2019 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Royalty Pharma (RPRX) total liabilities”, data as of 18 November 2026. https://funkfolio.com/stock/RPRX/total-liabilities

Underlying data: the company's filings with the SEC and Yahoo Finance.